Familial Pancreatic Ductal Adenocarcinoma
| Autor: | Kelly E. Diaz, Aimee L. Lucas |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Poor prognosis Pancreatic ductal adenocarcinoma endocrine system diseases Article Pathology and Forensic Medicine 03 medical and health sciences 0302 clinical medicine Risk Factors Internal medicine Pancreatic cancer medicine Screening method Carcinoma Humans Genetic Predisposition to Disease Genetic Testing Stage (cooking) Early Detection of Cancer Genetic testing medicine.diagnostic_test business.industry Genetic Diseases Inborn medicine.disease digestive system diseases Pancreatic Neoplasms 030220 oncology & carcinogenesis 030211 gastroenterology & hepatology business Carcinoma Pancreatic Ductal Rare disease |
| Zdroj: | The American Journal of Pathology. 189:36-43 |
| ISSN: | 0002-9440 |
| DOI: | 10.1016/j.ajpath.2018.06.026 |
| Popis: | Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage. Current screening methods are largely imaging based, but a more focused screening approach based on modifiable and nonmodifiable risk factors may improve the efficacy and likely outcomes of screening. In addition, the pathologic mechanisms that lead to the development of PDAC are discussed in an effort to further understand the targets of pancreatic cancer screening. The focus of this article will be inherited pancreatic cancer syndromes and familial pancreatic cancer, which together compose up to 10% of PDAC. Understanding the methods and targets of PDAC screening in high-risk individuals may translate to improved morbidity and mortality. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|